Moreover, we found that IL-15 can de novo induce the coordinated expression of NKp30 and its adaptor molecule FcεRIγ on CD8+ T cells, leading to the generation and expansion of functional NKp30+CD8+ T cells.23 Here, we aimed at arming those NKp30+CD8+ T cells with a tumor-specific TCR targeting HER2, to direct CD8+ T cell responses directly to the tumor. The gene discussed is NCR3; the disease is neoplasm.